GB2309033A - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB2309033A
GB2309033A GB9708980A GB9708980A GB2309033A GB 2309033 A GB2309033 A GB 2309033A GB 9708980 A GB9708980 A GB 9708980A GB 9708980 A GB9708980 A GB 9708980A GB 2309033 A GB2309033 A GB 2309033A
Authority
GB
United Kingdom
Prior art keywords
enzyme
chemical compounds
interaction
prodrug
reversed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9708980A
Other versions
GB2309033B (en
GB9708980D0 (en
Inventor
Christopher John Taylorson
Hendrikus Johannes Eggelte
Antonio Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
John Frederick Hennam
David Charles Blakey
Peter Robert Marsham
David William Heaton
David Huw Davies
Anthony Michael Slater
Laurent Francois And Hennequin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Priority to GB9708980A priority Critical patent/GB2309033B/en
Priority claimed from PCT/GB1995/002991 external-priority patent/WO1996020011A1/en
Publication of GB9708980D0 publication Critical patent/GB9708980D0/en
Publication of GB2309033A publication Critical patent/GB2309033A/en
Application granted granted Critical
Publication of GB2309033B publication Critical patent/GB2309033B/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Improved systems for targeted enzyme prodrug therapy, especially antibody directed enzyme prodrug therapy (ADEPT), in which the enzyme used is a mutated form of a host enzyme in which the natural host enzyme, such as ribonuclease, recognises its natural substrate by an ion pair interaction and this interaction is reversed ("reversed polarity") in the design of mutated enzyme and complementary prodrug.
GB9708980A 1994-12-23 1995-12-21 Chemical compounds Revoked GB2309033B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9708980A GB2309033B (en) 1994-12-23 1995-12-21 Chemical compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
PCT/GB1995/002991 WO1996020011A1 (en) 1994-12-23 1995-12-21 Chemical compounds
GB9708980A GB2309033B (en) 1994-12-23 1995-12-21 Chemical compounds

Publications (3)

Publication Number Publication Date
GB9708980D0 GB9708980D0 (en) 1997-06-25
GB2309033A true GB2309033A (en) 1997-07-16
GB2309033B GB2309033B (en) 1999-06-02

Family

ID=27267536

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9708980A Revoked GB2309033B (en) 1994-12-23 1995-12-21 Chemical compounds

Country Status (1)

Country Link
GB (1) GB2309033B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013095A2 (en) * 1993-11-12 1995-05-18 The Wellcome Foundation Limited Therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013095A2 (en) * 1993-11-12 1995-05-18 The Wellcome Foundation Limited Therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry, Vol. 2, No. 5, September 1991, pages349 to 352 *
Biosis Abs. Acc. No. 11601356 & Proc. Americ. Assoc. Cancer Ann., Vol. 36, No. 0, 18-22, 1995, p 482 *
Cancer Research, Vol. 54, April 1994, pages 2151 to 2159 *

Also Published As

Publication number Publication date
GB2309033B (en) 1999-06-02
GB9708980D0 (en) 1997-06-25

Similar Documents

Publication Publication Date Title
MX9704575A (en) Chemical compounds.
IL80883A0 (en) Process for altering the host range of bacillus thuringiensis toxins,and novel toxins produced thereby
AU6113396A (en) Novel high affinity human antibodies to tumor antigens
AU7261994A (en) Hydrazino-type radionuclide chelators having an n3s configuration
FI943389A0 (en) Bacillus from Bacillus, expression vector for such xylanase and other proteins, their host organisms and use
ES2102009T3 (en) TREATMENT FOR ASTHMA.
AU2724492A (en) Antibodies in immunosuppression
AUPM612494A0 (en) Treatment or prevention of helicobacter infection
MY114140A (en) Novel enzymes and prodrugs for use in antibody-directed enzyme prodrug therapy.
AU653560B2 (en) Device for magnetically treating fluids, gases or solids
AU7592394A (en) Assay of denatured lipoproteins
AU6793190A (en) Polyindanes as processing aid for engineering thermoplastics
GB2309033A (en) Chemical compounds
AU630815B1 (en) New process for the industrial preparation of 4-chloro-3-sulfamoyl-n-(2,3-dihydro-2-methyl-1h-indol-1-yl) benzamide
AU1559501A (en) Apoptosis inducing proteinaceous substance
AU591254B2 (en) Control system for inclined impact-type surface seismic source
AU3166295A (en) Imidazopyridine-azolidinones
EP1010761A4 (en) Gene
DK0870015T3 (en) Xylanases, genes encoding them, and their uses
AU633083B2 (en) Silica for dentifrice compositions, more particularly compatible with organic amino compounds
DK319384A (en) 1-0-ALKYL-3-AMINO-PROPAN-1,2-DIOL-2-0-PHOSPHOLIPIDES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
DK3086A (en) MICROORGANISM AND PLASMID FOR CONSTITUTIVE CREATINAMIDINO HYDROOLASE CREATION AND PROCEDURE FOR THEIR PREPARATION
AU7197091A (en) 6-substituted hexahydrobenz(cd)indoles
WO1998030687A3 (en) Protein containing an srcr domain
AU564040B2 (en) 1,2,3,4 - tetrahydro-1-aminomethyl-4-phenyl - isoquinolines

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)
773K Patent revoked under sect. 73(2)/1977

Free format text: PATENT REVOKED ON 20040614